TCR V β 13.1 Antibody (H131): sc-81762
- TCR V β 13.1 Antibody (H131) is a mouse monoclonal IgG2b κ TCR V β 13.1 antibody provided at 200 µg/ml
- raised against TCR V β 13.1 of human origin
- recommended for detection of TCR V β 13.1 of human origin by WB and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgGκ BP-HRP is the preferred secondary detection reagent for TCR V β 13.1 Antibody (H131) for WB applications. This reagent is now offered in a bundle with TCR V β 13.1 Antibody (H131) (see ordering information below). For additional m-IgGκ BP conjugates see our complete list of Mouse IgG Binding Proteins.
QUICK LINKS
SEE ALSO...
TCR V β 13.1 Antibody (H131) is a mouse monoclonal IgG2b kappa light chain antibody that detects the TCR V beta 13.1 protein of human origin by western blotting (WB) and flow cytometry (FCM). Anti-TCR V β 13.1 antibody (H131) is available in both non-conjugated and various conjugated forms, including phycoerythrin (PE) and fluorescein isothiocyanate (FITC), providing flexibility for different experimental needs. The T cell antigen receptor (TCR) plays a crucial role in the immune response by recognizing foreign antigens and initiating intracellular signaling that activates T cells, transitioning them from a dormant state to an active one. The TCR is a heterodimer, typically composed of either alpha and beta or gamma and delta chains, with approximately 95% of circulating T cells expressing the alpha/beta heterodimer. This diversity in TCR specificity is essential for the immune system to recognize a wide array of antigens, achieved through the somatic recombination of variable (V), diversity (D), and joining (J) gene segments during T cell development. The genes encoding the TCR beta and gamma chains are located in distinct loci, while the alpha and delta chain genes are found within a single locus. Notably, the synthesis of the TCR beta chain involves a complex process of joining D and J segments, followed by the addition of a V segment, culminating in the incorporation of a constant (C) segment. Understanding the structure and function of the TCR is vital, as genetic mutations in the TCR beta locus have been linked to the development of T cell lymphomas, highlighting the importance of TCR V β 13.1 monoclonal antibody (H131) in both research and clinical applications.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TCR V β 13.1 Antibody (H131) References:
- Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. | Rodríguez-Caballero, A., et al. 2008. Blood. 112: 4609-16. PMID: 18768393
- Expression of a murine polyclonal T cell receptor marker correlates with the use of specific members of the V beta 8 gene segment subfamily. | Behlke, MA., et al. 1987. J Exp Med. 165: 257-62. PMID: 2432150
- Donor lymphocytes may acquire cytolytic specificity to donor's engrafted hematopoietic cells after a hematopoietic stem cell allograft resulting in marrow failure. | Xing, H., et al. 2014. Clin Lab. 60: 455-62. PMID: 24697123
- Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor. | Staerz, UD., et al. 1985. J Immunol. 134: 3994-4000. PMID: 2580901
- Methods for the selection and growth of antigen-specific cytolytic T lines and clones bearing a defined T cell receptor beta chain marker. | Ito, M., et al. 1987. J Immunol Methods. 103: 229-37. PMID: 2959725
- Elevation of Memory Cytotoxic T Lymphocytes, Including Human T Lymphotropic Virus Type 1 Tax-Specific and Hepatitis Virus Type C-Specific Cytotoxic T Lymphocytes, in a Patient with Adult T-Cell Leukemia/Lymphoma and Hepatocellular Carcinoma. | Jo, T., et al. 2020. Case Rep Oncol. 13: 802-806. PMID: 32884522
- Inhibition of antigen-specific T cell activation by staphylococcal enterotoxins. | Dowd, JE., et al. 1995. J Immunol. 154: 1024-31. PMID: 7822779
- A mouse monoclonal antibody specific for the V beta 5.3 chain of the human TcR recognizes a subgroup of the mouse TcR V beta 8.2 chains. | Bleux, C., et al. 1995. J Leukoc Biol. 57: 491. PMID: 7884322
- Dominant V beta 8 gene usage in response to TNP: failure to use other V beta chains following removal of V beta 8+ T cells by monoclonal antibody in vivo. | Dieli, F., et al. 1994. Immunology. 82: 99-105. PMID: 8045598
- T cell vaccination against autoimmune diabetes in nonobese diabetic mice. | Formby, B. and Shao, T. 1993. Ann Clin Lab Sci. 23: 137-47. PMID: 8096128
- Skewed distribution of TCR V alpha 7-bearing T cells within tumor-infiltrating lymphocytes of HLA-A24(9)-positive patients with malignant glioma. | Ebato, M., et al. 1993. Immunol Lett. 39: 53-64. PMID: 8144191
- Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan. | Mokyr, MB., et al. 1993. J Immunol. 151: 4838-46. PMID: 8409442
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TCR V β 13.1 Antibody (H131) | sc-81762 | 200 µg/ml | $316.00 | |||
TCR V β 13.1 Antibody (H131): m-IgGκ BP-HRP Bundle | sc-534488 | 200 µg Ab; 40 µg BP | $354.00 | |||
TCR V β 13.1 Antibody (H131) FITC | sc-81762 FITC | 200 µg/ml | $330.00 | |||
TCR V β 13.1 Antibody (H131) PE | sc-81762 PE | 200 µg/ml | $343.00 |